Skip to main content

Table 1 Subjects’ demographic and clinical characteristics.a

From: Effect of Cigarette Smoke Exposure and Structural Modifications on the α-1 Antitrypsin Interaction with Caspases

  No clinical diagnosis of COPD nonsmoker No clinical diagnosis of COPD smoker COPD nonsmoker COPD smoker P
  (n = 8) (n = 8) (n = 5) (n = 8)  
Age, years 53.5 ± 6.6 39.5 ± 7.7 63.8 ± 3.4 52.25 ± 3.6 0.09
Race, white % 87.5 62.5 100 75 0.37
Cigarette smoking, pack-years 7.3 ± 4.1 15.0 ± 5.6 74 ± 12.4 47.5 ± 15.4 0.0008
Current smokers, % 0 100 0 100 <0.0001
Cachexia, % 0 0 20 37.5 0.0768
Asthma, % 12.5 12.5 20 0 0.68
FEV1, % predicted NA NA 50.6 ± 11.986 44.88 ± 6.337 0.6507
FEV1/FVC, % NA NA 53.2 ± 8.941 58.5 ± 5.039 0.586
Emphysema diagnosed radiographically, % NA NA 80 50 0.56
Oral or inhaled corticosteroid use, % 25 12.5 100 75 0.003
Other medications (β-agonist,      
anticholinergic, methylxantine), % 12.5 12.5 100 100 <0.0001
  1. aMean ± SEM. FEV1, forced expiratory volume in 1 s; NA, no data available; FVC, forced vital capacity.